Cargando…
n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease
DNA telomere shortening associates with the age-related increase cardiovascular disease (CVD) risk. Reducing oxidative stress, could modify telomere erosion during cell replication, and CVD risk in patients with chronic kidney disease (CKD). The effect of n-3 fatty acids and coenzyme Q10 (CoQ) on te...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808901/ https://www.ncbi.nlm.nih.gov/pubmed/27007392 http://dx.doi.org/10.3390/nu8030175 |
_version_ | 1782423549135290368 |
---|---|
author | Barden, Anne O’Callaghan, Nathan Burke, Valerie Mas, Emile Beilin, Lawrence J. Fenech, Michael Irish, Ashley B. Watts, Gerald F. Puddey, Ian B. Huang, Rae-Chi Mori, Trevor A. |
author_facet | Barden, Anne O’Callaghan, Nathan Burke, Valerie Mas, Emile Beilin, Lawrence J. Fenech, Michael Irish, Ashley B. Watts, Gerald F. Puddey, Ian B. Huang, Rae-Chi Mori, Trevor A. |
author_sort | Barden, Anne |
collection | PubMed |
description | DNA telomere shortening associates with the age-related increase cardiovascular disease (CVD) risk. Reducing oxidative stress, could modify telomere erosion during cell replication, and CVD risk in patients with chronic kidney disease (CKD). The effect of n-3 fatty acids and coenzyme Q10 (CoQ) on telomere length was studied in a double-blind placebo-controlled trial in CKD. Eighty-five CKD patients were randomized to: n-3 fatty acids (4 g); CoQ (200 mg); both supplements; or control (4 g olive oil), daily for 8 weeks. Telomere length was measured in neutrophils and peripheral blood mononuclear cells (PBMC) at baseline and 8 weeks, with and without correction for cell counts. Main and interactive effects of n-3 fatty acids and CoQ on telomere length were assessed adjusting for baseline values. F(2)-isoprostanes were measured as markers of oxidative stress. There was no effect of n-3 fatty acids or CoQ on neutrophil or PBMC telomere length. However, telomere length corrected for neutrophil count was increased after n-3 fatty acids (p = 0.015). Post-intervention plasma F(2)-isoprostanes were negative predictors of post-intervention telomere length corrected for neutrophil count (p = 0.025).The effect of n-3 fatty acids to increased telomere length corrected for neutrophil count may relate to reduced oxidative stress and increased clearance of neutrophils with shorter telomeres from the circulation. This may be a novel mechanism of modifying CVD risk in CKD patients. |
format | Online Article Text |
id | pubmed-4808901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-48089012016-04-04 n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease Barden, Anne O’Callaghan, Nathan Burke, Valerie Mas, Emile Beilin, Lawrence J. Fenech, Michael Irish, Ashley B. Watts, Gerald F. Puddey, Ian B. Huang, Rae-Chi Mori, Trevor A. Nutrients Article DNA telomere shortening associates with the age-related increase cardiovascular disease (CVD) risk. Reducing oxidative stress, could modify telomere erosion during cell replication, and CVD risk in patients with chronic kidney disease (CKD). The effect of n-3 fatty acids and coenzyme Q10 (CoQ) on telomere length was studied in a double-blind placebo-controlled trial in CKD. Eighty-five CKD patients were randomized to: n-3 fatty acids (4 g); CoQ (200 mg); both supplements; or control (4 g olive oil), daily for 8 weeks. Telomere length was measured in neutrophils and peripheral blood mononuclear cells (PBMC) at baseline and 8 weeks, with and without correction for cell counts. Main and interactive effects of n-3 fatty acids and CoQ on telomere length were assessed adjusting for baseline values. F(2)-isoprostanes were measured as markers of oxidative stress. There was no effect of n-3 fatty acids or CoQ on neutrophil or PBMC telomere length. However, telomere length corrected for neutrophil count was increased after n-3 fatty acids (p = 0.015). Post-intervention plasma F(2)-isoprostanes were negative predictors of post-intervention telomere length corrected for neutrophil count (p = 0.025).The effect of n-3 fatty acids to increased telomere length corrected for neutrophil count may relate to reduced oxidative stress and increased clearance of neutrophils with shorter telomeres from the circulation. This may be a novel mechanism of modifying CVD risk in CKD patients. MDPI 2016-03-19 /pmc/articles/PMC4808901/ /pubmed/27007392 http://dx.doi.org/10.3390/nu8030175 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Barden, Anne O’Callaghan, Nathan Burke, Valerie Mas, Emile Beilin, Lawrence J. Fenech, Michael Irish, Ashley B. Watts, Gerald F. Puddey, Ian B. Huang, Rae-Chi Mori, Trevor A. n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease |
title | n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease |
title_full | n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease |
title_fullStr | n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease |
title_full_unstemmed | n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease |
title_short | n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease |
title_sort | n-3 fatty acid supplementation and leukocyte telomere length in patients with chronic kidney disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808901/ https://www.ncbi.nlm.nih.gov/pubmed/27007392 http://dx.doi.org/10.3390/nu8030175 |
work_keys_str_mv | AT bardenanne n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease AT ocallaghannathan n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease AT burkevalerie n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease AT masemile n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease AT beilinlawrencej n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease AT fenechmichael n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease AT irishashleyb n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease AT wattsgeraldf n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease AT puddeyianb n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease AT huangraechi n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease AT moritrevora n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease |